AVH.AX : Summary for AVITA MED FPO - Yahoo Finance

U.S. Markets closed

Avita Medical Limited (AVH.AX)


ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.09-0.01 (-5.00%)
At close: 4:10PM AEDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.10
Open0.10
Bid0.09 x
Ask0.10 x
Day's Range0.09 - 0.10
52 Week Range0.09 - 0.15
Volume251,869
Avg. Volume291,595
Market Cap68.21M
Beta0.67
PE Ratio (TTM)-6.33
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wireyesterday

    Avita Medical to Present at Needham Healthcare Conference

    Avita Medical Limited , a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that Adam Kelliher, Avita’s Chief Executive Officer will present at the 16th Annual Needham Healthcare Conference on 4 April 2017.

  • Business Wire9 days ago

    Avita Announces Receipt of $975K R&D Tax Incentive

    Avita Medical Limited , a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office of A$974,908 for the financial year ending 30 June 2016.

  • Business Wire18 days ago

    Avita Medical Announces Last Patient Visit in U.S. Pivotal Trial

    Avita Medical Limited , a regenerative medicine company focused on the treatment of wounds and skin defects, has collected long-term follow-up data from the final patient enrolled in its pivotal FDA trial of the ReCell® Autologous Cell Harvesting Device for the treatment of burns, and achieved a key milestone in its U.S.